Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;328(17):1730-1739.
doi: 10.1001/jama.2022.19061.

Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection

Affiliations

Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection

Christine Johnston et al. JAMA. .

Abstract

Importance: Herpes simplex virus type 1 (HSV-1) is the leading cause of first-episode genital herpes in many countries.

Objective: To inform counseling messages regarding genital HSV-1 transmission, oral and genital viral shedding patterns among persons with first-episode genital HSV-1 infection were assessed. The trajectory of the development of HSV-specific antibody and T-cell responses was also characterized.

Design, setting, and participants: Prospective cohort followed up for up to 2 years, with 82 participants followed up between 2013 and 2018. Participants were recruited from sexual health and primary care clinics in Seattle, Washington. Persons with laboratory-documented first-episode genital HSV-1 infection, without HIV infection or current pregnancy, were referred for enrollment.

Exposures: First-episode genital HSV-1 infection.

Main outcomes and measures: Genital and oral HSV-1 shedding and lesion rates at 2 months, 11 months, and up to 2 years after initial genital HSV-1 infection. Participants self-collected oral and genital swabs for HSV polymerase chain reaction testing for 30 days at 2 and 11 months and up to 2 years after diagnosis of genital HSV-1. Blood samples were collected at serial time points to assess immune responses to HSV-1. Primary HSV-1 infection was defined as absent HSV antibody at baseline or evolving antibody profile using the University of Washington HSV Western Blot. HSV-specific T-cell responses were detected using interferon γ enzyme-linked immunospot.

Results: Among the 82 participants, the median (range) age was 26 (16-64) years, 54 (65.9%) were women, and 42 (51.2%) had primary HSV-1 infection. At 2 months, HSV-1 was detected from the genital tract in 53 participants (64.6%) and in the mouth in 24 participants (29.3%). Genital HSV-1 shedding was detected on 275 of 2264 days (12.1%) at 2 months and declined significantly to 122 of 1719 days (7.1%) at 11 months (model-predicted rate, 6.2% [95% CI, 4.3%-8.9%] at 2 months vs 3.2% [95% CI, 1.8%-5.7%] at 11 months; relative risk, 0.52 [95% CI, 0.29-0.93]). Genital lesions were rare, reported on 65 of 2497 days (2.6%) at 2 months and 72 of 1872 days (3.8%) at 11 months. Oral HSV-1 shedding was detected on 88 of 2247 days (3.9%) at 2 months. Persons with primary HSV-1 infection had a higher risk of genital shedding compared with those with nonprimary infection (model-predicted rate, 7.9% [95% CI, 5.4%-11.7%] vs 2.9% [95% CI, 1.7%-5.0%]; relative risk, 2.75 [95% CI, 1.40-5.44]). Polyfunctional HSV-specific CD4+ and CD8+ T-cell responses were maintained during the follow-up period.

Conclusions and relevance: Genital HSV-1 shedding was frequent after first-episode genital HSV-1, particularly among those with primary infection, and declined rapidly during the first year after infection.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Johnston reported receiving grants from National Institutes of Health/National Institute of Allergy and Infectious Diseases during the conduct of the study and personal fees from AbbVie, grants from Gilead, royalties from UpToDate, and personal fees from GlaxoSmithKline outside the submitted work. Dr Gunby reported being an IDSA Education and Research Foundation Scholarship recipient during the conduct of the study. Dr Koelle reported receiving grants from Sanofi (specifically a contract to perform immunogenicity assays for HSV-2 vaccine clinical trial) outside the submitted work and having a patent for HSV vaccine candidates with royalties paid from Immune Design Corporation; institutionally (university) owned patents were licensed by University of Washington to Immune Design Corporation and royalty payments were received. Dr Wald reported receiving grants from NIH during the conduct of the study and grants from GlaxoSmithKline and Sanofi and personal fees from Aicuris, X-Vax, Crozet, Auritec, and DxNow outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Genital and Oral Herpes Simplex Virus Type 1 (HSV-1) Shedding Rates
All participants are included; those who completed only the first session are indicated by a dot for the second session. Twenty-eight participants did not have any genital shedding detected and 49 participants did not have any oral shedding detected. Shedding rates are calculated by dividing the number of days with HSV detected by the total number of days with swabs collected. Study participants are plotted in reverse rank order from least to greatest shedding rate. The order of study participants is not equivalent in panels A and B, and the participant numbers do not relate directly to viral genome isolate numbers in eFigure 3 in the Supplement.
Figure 2.
Figure 2.. Bivariable and Multivariable Risk Factors Associated With Genital and Oral Herpes Simplex Virus Type 1 (HSV-1) Shedding
For this analysis, those with unknown acquisition type are grouped with those with nonprimary infection. For the comparison between first and second session, the model does not distinguish primary from nonprimary or unknown acquisition type. For the comparison between nonprimary unknown and primary the model does not distinguish the first from the second session. The multivariable model included an interaction term between session and acquisition type. In multivariable models including both age and sex, neither age nor sex contributed to the model in estimating shedding frequencies, so those measures were removed in backward elimination. Forest plots indicate the point estimate and 95% CI for each comparison. The reference is indicated by a box over the midline without a CI.
Figure 3.
Figure 3.. Cellular Immune Responses Measured Over Time for the First 20 Participants With Primary Genital Herpes Simplex Virus Type 1 (HSV-1)
Each line represents the time course for a single participant, and participants are represented by the same line color for both graphs. IFN indicates interferon; PBMC, peripheral blood mononuclear cells.

Comment in

References

    1. Spicknall IH, Flagg EW, Torrone EA. Estimates of the prevalence and incidence of genital herpes, United States, 2018. Sex Transm Dis. 2021;48(4):260-265. doi:10.1097/OLQ.0000000000001375 - DOI - PubMed
    1. Kreisel KM, Spicknall IH, Gargano JW, et al. . Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex Transm Dis. 2021;48(4):208-214. doi:10.1097/OLQ.0000000000001355 - DOI - PMC - PubMed
    1. Chesson HW, Spicknall IH, Bingham A, et al. . The estimated direct lifetime medical costs of sexually transmitted infections acquired in the United States in 2018. Sex Transm Dis. 2021;48(4):215-221. doi:10.1097/OLQ.0000000000001380 - DOI - PMC - PubMed
    1. Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect. 2009;85(6):416-419. doi:10.1136/sti.2008.033902 - DOI - PubMed
    1. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2–United States, 1999-2010. J Infect Dis. 2014;209(3):325-333. doi:10.1093/infdis/jit458 - DOI - PubMed

Publication types